Arcutis Shares New Dermatology Data On ZORYVE And Steroid Use; Stock Up

Arcutis Biotherapeutics announced that new data on ZORYVE (roflumilast) and real-world research on long-term topical corticosteroid use were presented at the European Academy of Dermatology and Venereology Congress and the Fall Clinical Dermatology Conference. The report provides no study results, numerical findings, or market reaction.